---
title: Synendos Therapeuthics
date: 2020-11-13T11:37:02Z
modified: 2026-08-12T08:52:33Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/synendos-therapeuthics/"
type: portfolio
status: publish
excerpt: ""
wpid: 83422
language:
  - English
post_translations:
  - pll_5fae6ee8923ee
branchen22:
  - Neurology
sectors:
  - Pharmaceuticals
focus_areas:
  - Neuromodulation
timestamp: 2026-08-12T08:52:33Z
tags:
  - English
  - pll_5fae6ee8923ee
  - Neurology
  - Pharmaceuticals
  - Neuromodulation
---

## Beschreibungstext

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.

## Unternehmenswebsite

https://www.synendos.com/

## Adresse

Gewerbestrasse, 24
4123 – Allschwil (Switzerland)

## Kontakt

Array